ALNT — Allient
Good industrial story. Awkward starting valuation.
Allient makes motion-control and power systems across automation, aerospace and defense, medical, semiconductor equipment, robotics and data-center power. I like the operating direction. I do not like paying a price that already seems to know the direction is good.
Allient is the kind of company where I start liking the business before the math has given me any permission to like the stock. The operating story is improving. The return from the research price still kind of sucks.
Why I care about this one
Allient sells motors, actuators, gearing, encoders, controllers, transformers and power-quality equipment. None of that sounds especially glamorous, which is kind of the appeal. Those components sit inside automation, aerospace and defense, medical equipment, semiconductor tools, robotics and data-center infrastructure.
The company is also trying to sell more integrated motion and power systems instead of remaining a loose collection of components. If that works, the customer relationship gets stickier and the margin profile can improve.
Q2 2026 made the story harder to ignore. Revenue grew about 10%, gross margin improved to 34.9%, operating income rose 34%, bookings jumped 49%, and backlog reached $298M.
That is real progress. Bookings were about 1.31x revenue for the quarter too. Nice signal. I am just not going to pretend backlog is guaranteed revenue because the number looks good.
The part I like is the mix shift toward higher-value motion and power applications while bookings, backlog and margins are all improving. The part I do not want to kid myself about is that attractive end markets do not automatically become attractive shareholder returns.
Q2 2026
Primary sources: Q2 2026 Form 10-Q — SEC ↗ · Sep. 26, 2026 Research Note — frozen snapshot ↗
The Sep. 26 Research Note is still the living baseline. Q2 bookings, backlog and margins all improved, but the $116.01 reference price still asks for too much growth for too little return. Capital Allocation stays at 7.0/10.
Bookings convert cleanly, margins keep moving up, data-center and aerospace/defense mix becomes large enough to actually matter, debt keeps falling and EPS estimates rise materially faster than the stock.
Backlog does not convert, margin progress stalls, acquisitions add debt without adding per-share value, the sexy end markets stay too small to move the numbers, or the stock stays expensive while growth normalizes.
Why I passed
At the $116.01 reference price, the base case assumed 17% EPS growth for five years and a 24x exit multiple yet still produced only about 4.4% annualized. Interesting business; not enough expected return.
A no-allocation decision is dated, not a permanent ban. New price, new evidence or a different portfolio context can reopen the work.
At the $116.01 reference price, the base case assumed 17% EPS growth for five years and a 24x exit multiple yet still produced only about 4.4% annualized. Interesting business; not enough expected return.
Valuation & scenario math
The September 26 research note used a $116.01 reference price. Consensus 2026 EPS was about $2.74, which put the stock near 42x earnings.
The reverse math is what stopped me. Even asking for only a 10% annualized five-year return required roughly $7.47 of 2031 EPS at a 25x exit multiple. That is about 22% annual EPS growth from the 2026 estimate.
The base case was arguably a good business outcome: 17% EPS growth for five years and a 24x terminal multiple. It still only produced about 4.4% annualized from the reference price.
That is not enough for me.
I used reverse math because saying '42x feels expensive' is not really analysis. The result was worse: even a strong operating outcome still left a weak five-year return from the reference price. So I am watching it, not trying to convince myself the quality makes the valuation disappear.
“My current view” is the output of my dated valuation framework, not a magical buy instruction. A BUY still has to beat the expected return of what I already own and the index before it gets actual money.
Expected return has to improve
At the $116.01 research price, the base case already assumed 17% EPS growth for five years and a 24x exit multiple and still only got to about 4.4% annualized. That is kind of the whole issue. Either the price gets much better or the earnings power needs to outrun the stock.
The Sep. 26 research model is still the baseline. The annoying part is that the business can execute really well and I can still earn a mediocre return because the starting multiple is doing me no favors.
| Normalized EPS today | $2.74 |
| Annual EPS growth | 17% |
| EPS by Sep 25, 2031 | ~$6.01 |
| Terminal P/E | 24x |
| Implied base price | ~$144/share |
The base case is basically ~$6.01 of Sep 25, 2031 EPS at 24x, or about $144/share. Same math, just without making the reader decode equation soup.
| Case | What has to be true | Target range | Total return* | Annualized return* |
|---|---|---|---|---|
| Bear | 8% annual EPS growth · 18x terminal P/E. Growth cools, margin expansion gets harder and the market eventually values Allient like a normal industrial compounder. | $67–$78 center ~$72 | -37.5% | -9.0% |
| Base | 17% annual EPS growth · 24x terminal P/E. Bookings convert, margins improve and earnings compound at a genuinely strong rate, but the terminal multiple normalizes. | $134–$154 center ~$144 | +24.3% | +4.4% |
| Bull | 24% annual EPS growth · 30x terminal P/E. Integrated motion/power systems and higher-growth end markets drive exceptional EPS growth while the market still awards a premium multiple. | $224–$258 center ~$241 | +107.7% | +15.7% |
*The static returns use the dated reference price. The annualized figure on the live page also refreshes from the current quote. For shorter model horizons, annualizing can make the number look ridiculous, so I care about total return and the underlying milestones at least as much.
Capital allocation
Pretty coherent business. Still not enough return for me.
Organic growth, better margins, stronger bookings/backlog and debt reduction all look sensible. The acquisitions also fit the strategy. I just want more evidence that all of that shows up per share, and the modest SBC/share leakage is enough to keep the score from getting too generous.
Stage-relative, not some objective rating-agency grade. The number is there to force the judgment into the open. See the rubric →
What management is actually doing with the cash
Allient has been using acquisitions to broaden the portfolio and push toward more integrated motion and power systems. That can absolutely make the business better. It can also just make the company bigger. Debt, integration and goodwill are why I want the per-share proof before I give the acquisition strategy too much credit.
What would make me reconsider
I do not need some dramatic crash to get interested. I just need more of the future return to be left for the buyer.
That can happen through a lower share price, faster earnings growth, better margins, or enough operating evidence that the old assumptions become obviously too conservative. Until one of those happens, zero dollars is a perfectly valid position size.
What can break this
This is still an industrial company with cyclical end markets, acquisition and integration risk, debt, tariff exposure and competitors with more resources. Attractive nouns like data centers, robotics and defense do not automatically become earnings.
The bigger risk is much simpler: I can be completely right about the company getting better and still make a mediocre return because I paid too much.
If bookings stop converting, margin improvement stalls, debt rises for weak acquisitions, or the higher-growth end markets never become meaningful enough to move per-share earnings, the quality-upgrade thesis weakens.
So for now, zero dollars. I like the company story more than I like the stock from the September research price. If the math changes, I will happily reopen it. There is no urgency to make the portfolio agree with the business just because I enjoyed the research.